BridgeMD
New treatment option for Coronary Artery Disease
Official title COronoary Microcirculation Analysis NETwork
ClinicalTrials.gov ID: NCT07498231
What this study is testing
- What it's testing
- COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.
- Time commitment: about 21 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- a. Chronic coronary syndrome c. Anginal symptoms \> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e...
You likely can't join if
- Angiographically significant coronary artery stenosis or FFR \< 0.8
- Renal insufficiency with eGFR \< 30 ml/min/1.73 m²
- Left ventricular ejection fraction \< 40%
- Hypertrophic cardiomyopathy
- Acute coronary syndrome within \< 90 days
- Percutaneous coronary intervention (PCI) within \< 90 days
See the full eligibility criteria
- a. Chronic coronary syndrome c. Anginal symptoms \> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of informed consent to participate in the study
- Angiographically significant coronary artery stenosis or FFR \< 0.8
- Renal insufficiency with eGFR \< 30 ml/min/1.73 m²
- Left ventricular ejection fraction \< 40%
- Hypertrophic cardiomyopathy
- Acute coronary syndrome within \< 90 days
- Percutaneous coronary intervention (PCI) within \< 90 days
- Previous coronary artery bypass grafting (CABG)
- Anemia \< 10 g/dL or thrombocytopenia \< 100,000/µL
- Intraventricular conduction disturbances preventing ST-T segment assessment
- Severe concomitant valvular heart disease
- Active malignancy
- Type 1 diabetes mellitus
- Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing \> 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly...
- Pregnancy
- Heart failure ≥ NYHA class III
- Asthma or COPD with severe irreversible airflow obstruction
- Atrial fibrillation
- Second- or third-degree atrioventricular block without pacemaker implantation (IPG)
- Manifest pre-excitation on ECG or history of AVRT episodes without prior ablation of the accessory pathway
The study team makes the final eligibility decision.
Where it's taking place
- Bialystok, Poland
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 21 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bialystok, Poland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.